Clinical Trial

Feasibility and Acceptability of Amani

Study acronym: Amani
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Adults with sickle cell disease (SCD) experience severe pain, emotional distress, and social isolation that diminish their quality of life. This project will test Amani, a novel virtual reality supportive care intervention designed to improve coping skills and strengthen peer support. If feasible and acceptable, Amani offers an accessible digital supportive care intervention to improve psychological well-being and quality of life among individuals living with SCD.
Protocol Amendment History 2 changes
critical Phase changed: Early Phase 1 -> Phase 1/2 2026-08-08
minor Completion pushed: 2028-04-30 -> 2028-06-30 2026-08-08
Trial Details
NCT Number NCT07648043
Lead Sponsor Massachusetts General Hospital
Collaborators: Ascent
Conditions Sickle Cell Disease
Enrollment 40 participants
Start Date 2026-11-01
Primary Completion 2028-02-28 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-07